- Home
- NCMI vs AURA Comparison
NCMI vs AURA Comparison
Compare NCMI & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCMI
- AURA
- Stock Information
- Founded
- NCMI 2005
- AURA 2007
- Country
- NCMI United States
- AURA United States
- Employees
- NCMI N/A
- AURA N/A
- Industry
- NCMI Advertising
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- NCMI Consumer Discretionary
- AURA Health Care
- Exchange
- NCMI Nasdaq
- AURA Nasdaq
- Market Cap
- NCMI 647.2M
- AURA 572.0M
- IPO Year
- NCMI 2007
- AURA 2021
- Fundamental
- Price
- NCMI $6.81
- AURA $9.03
- Analyst Decision
- NCMI Strong Buy
- AURA Strong Buy
- Analyst Count
- NCMI 4
- AURA 4
- Target Price
- NCMI $7.56
- AURA $23.00
- AVG Volume (30 Days)
- NCMI 490.0K
- AURA 186.8K
- Earning Date
- NCMI 11-05-2024
- AURA 11-12-2024
- Dividend Yield
- NCMI N/A
- AURA N/A
- EPS Growth
- NCMI N/A
- AURA N/A
- EPS
- NCMI N/A
- AURA N/A
- Revenue
- NCMI $245,300,000.00
- AURA N/A
- Revenue This Year
- NCMI $47.48
- AURA N/A
- Revenue Next Year
- NCMI $18.60
- AURA N/A
- P/E Ratio
- NCMI N/A
- AURA N/A
- Revenue Growth
- NCMI 47.68
- AURA N/A
- 52 Week Low
- NCMI $3.64
- AURA $6.63
- 52 Week High
- NCMI $7.39
- AURA $12.38
- Technical
- Relative Strength Index (RSI)
- NCMI 50.29
- AURA 37.58
- Support Level
- NCMI $6.62
- AURA $10.48
- Resistance Level
- NCMI $6.82
- AURA $11.29
- Average True Range (ATR)
- NCMI 0.28
- AURA 0.55
- MACD
- NCMI -0.01
- AURA -0.27
- Stochastic Oscillator
- NCMI 50.85
- AURA 12.40
About NCMI National CineMedia Inc.
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.